SCHEMBL1421341

SCHEMBL1421341

O=C1NC(=O)C(c2ccc(F)cc2)N1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 1.00
MAPT P10636 2/20 0.54
ALDH1A1 P00352 1/20 0.54
LMNA P02545 2/20 0.51
GAA P10253 3/20 0.49
GSK3B P49841 4/20 0.49
BACE1 P56817 4/20 0.49
ABL1 P00519 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
KDM4E B2RXH2 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
RXFP1 Q9HBX9 1/20 0.41
POLB P06746 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8270572 1.00 TDP1 (1.00) TDP1MAPTALDH1A1LMNAGAA
SCHEMBL13527924 0.89 TDP1 (0.80) TDP1MAPTALDH1A1LMNAGAA
SCHEMBL7167731 0.82 TDP1 (0.69) TDP1MAPTALDH1A1LMNAGAA
SCHEMBL1421442 0.81 TDP1 (0.68) TDP1MAPTALDH1A1GAAGSK3B
SCHEMBL9690927 0.80 TDP1 (0.67) TDP1MAPTALDH1A1LMNAGAA
SCHEMBL8252775 0.80 TDP1 (0.67) TDP1MAPTALDH1A1LMNAGAA
SCHEMBL9000125 0.80 TDP1 (0.67) TDP1MAPTALDH1A1LMNAGAA
SCHEMBL1014744 0.80 TDP1 (0.67) TDP1MAPTALDH1A1LMNAGAA
SCHEMBL11653963 0.80 TDP1 (0.67) TDP1MAPTALDH1A1LMNAGAA
SCHEMBL28470699 0.80 TDP1 (0.67) TDP1MAPTALDH1A1LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109824531-B Method for continuously and rapidly preparing DL-phenylglycine and analogues thereof 天宝动物营养科技股份有限公司 2022-08-23 CN disclosed
CN-109824531-A Method for continuously and rapidly preparing DL-phenylglycine and analogues thereof 禄丰天宝磷化工有限公司 2019-05-31 CN disclosed
US-20110098323-A1 INHIBITORS OF BACTERIAL BIOFILM FORMATION MICROBIOTIX, INC. (US) 2011-04-28 US disclosed
EP-2296476-A1 INHIBITORS OF BACTERIAL BIOFILM FORMATION Microbiotix, Inc. (US) 2011-03-23 EP disclosed
WO-2009142720-A1 INHIBITORS OF BACTERIAL BIOFILM FORMATION MICROBIOTIX, INC. (US) 2009-11-26 WO disclosed
US-5338859-A Reacting a hydantoin with a calcium base; crystallization; precipitation; separation HOECHST CELANESE CORPORATION (US) 1994-08-16 US disclosed
US-4436910-A SAPONIFICATION DEGUSSA AKTIENGESELLSCHAFT (DE) 1984-03-13 US disclosed
US-4094741-A CULTURES, ASYMMETRIC HYDROLYSIS KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JA) 1978-06-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098323-A1 INHIBITORS OF BACTERIAL BIOFILM FORMATION BLVRB, TFPI, FOSB TDP1 3036/4885MAPT 4065/4885ALDH1A1 1408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.